KalVista Pharmaceuticals (KALV) Non Operating Investment Income (2020 - 2025)
KalVista Pharmaceuticals (KALV) reported Non Operating Investment Income of $587000.0 for Q3 2025, up 85.17% on a YoY basis from $317000.0 in Q3 2024, and up 59.08% sequentially from $369000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Non Operating Investment Income (2020 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 6 years of Non Operating Investment Income data on file, last reported at $587000.0 in Q3 2025.
- For the quarter ending Q3 2025, Non Operating Investment Income rose 85.17% year-over-year to $587000.0; the trailing twelve-month figure through Jul 2025 stood at $1.9 million (up 44.73% YoY), and the FY2025 full-year result was $1.6 million, up 17.81% from the prior year.
- Non Operating Investment Income improved to $587000.0 in Q3 2025, from $369000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $649000.0 in Q4 2024 to a low of -$285000.0 in Q2 2022.
- A 5-year average of $142444.4 and a median of $38500.0 in 2021 frame the typical range for Non Operating Investment Income.
- Across the five-year window, Non Operating Investment Income slumped 630.77% in 2022 and surged 22000.0% in 2024, its largest moves.
- Tracing KALV's Non Operating Investment Income over 5 years: stood at -$97000.0 in 2021, then increased by 28.87% to -$69000.0 in 2022, then soared by 962.32% to $595000.0 in 2023, then rose by 9.08% to $649000.0 in 2024, then retreated by 9.55% to $587000.0 in 2025.
- Business Quant data shows KALV's Non Operating Investment Income at $587000.0 in Q3 2025, $369000.0 in Q2 2025, and $649000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | 587,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 587,000.00 |
| Jul 31, 2025 | 587,000.00 |
| Apr 30, 2025 | 369,000.00 |
| Apr 30, 2025 | 369,000.00 |
| Oct 31, 2024 | 649,000.00 |
| Oct 31, 2024 | 649,000.00 |
| Jul 31, 2024 | 317,000.00 |
| Jul 31, 2024 | 317,000.00 |
| Apr 30, 2024 | 195,000.00 |
| Apr 30, 2024 | 195,000.00 |
| Jan 31, 2024 | 221,000.00 |
| Jan 31, 2024 | 221,000.00 |
| Oct 31, 2023 | 595,000.00 |
| Oct 31, 2023 | 595,000.00 |
| Jul 31, 2023 | 314,000.00 |
| Jul 31, 2023 | 314,000.00 |
| Apr 30, 2023 | -55,000.00 |
| Apr 30, 2023 | -55,000.00 |
| Jan 31, 2023 | 1,000.00 |
| Jan 31, 2023 | 1,000.00 |